by DealForma Analysts | Feb 10, 2022 | Deal of the Month
Deal of the Month January 2022 Top Biopharma Deal: Beam – Pfizer In Vivo Base Editing and Delivery Programs for Rare Diseases January 2022 Top Biopharma Deal Upfront Beam research partnership with Pfizer with a license option for up to three therapies for rare...
by DealForma Analysts | Jan 10, 2022 | Deal of the Month
Deal of the Month December 2021 Top Biopharma Deal: Foghorn – Loxo using Gene Traffic Control for New Oncology Treatments December 2021 Top Biopharma Deal Upfront Foghorn partnership with Loxo (Eli Lilly) for selective BRM oncology therapies Announced: December...
by DealForma Analysts | Dec 8, 2021 | Deal of the Month
Deal of the Month November 2021 Top Biopharma Deal: Sanofi – Owkin artificial intelligence and federated learning platform to advance Sanofi’s oncology pipeline November 2021 Top Biopharma Deal Upfront Owkin discovery and development deal with Sanofi for...
by DealForma Analysts | Nov 5, 2021 | Deal of the Month
Deal of the Month October 2021 Top Biopharma Deal: Xencor – Janssen for Plamotamab and XmAb Bispecific Antibodies Top Biopharma Partnership by Upfront Cash and Equity October 2021 Xencor development and commercialization deal with Janssen for plamotamab and XmAb...
by DealForma Analysts | Oct 7, 2021 | Deal of the Month
Deal of the Month September 2021 Top Biopharma Deal: REGENXBIO – AbbVie for RBX-314 for wet AMD, diabetic retinopathy Top Biopharma Partnership by Upfront Cash and Equity September 2021 REGENXBIO development and commercialization deal with AbbVie for RGX-314...
by DealForma Analysts | Sep 8, 2021 | Deal of the Month
Deal of the Month August 2021 Top Biopharma Deal: RemeGen – Seagen HER2-targeted ADC, Disitamab Vedotin for Solid Tumors Top Biopharma Partnership by Upfront Cash and Equity August 2021 RemeGen development and commercialization deal with Seagen for disitamab...
by DealForma Analysts | Aug 1, 2021 | Deal of the Month
Deal of the Month Top Biopharma Deal July 2021: Arvinas – Pfizer ARV-471 PROTAC Protein Degrader for ER+/HER2- Breast Cancer Top Biopharma Partnership by Upfront Cash and Equity July 2021 Arvinas development and commercialization deal with Pfizer for ARV-471...
by DealForma Analysts | Jul 1, 2021 | Deal of the Month
Deal of the Month Top Biopharma Deal June 2021: iTeos – GSK for EOS-448 anti-TIGIT mAb for Solid Tumors Top Biopharma Partnership by Upfront Cash and Equity June 2021 iTeos development and commercialization deal with GSK for EOS-448 Announced: June 14, 2021...
by DealForma Analysts | Jun 5, 2021 | Deal of the Month
Deal of the Month Top Biopharma Deal May 2021: Agenus – BMS for AGEN-1777 Bispecific Anti-TIGIT Antibody for Non-Small Cell Lung Cancer Top Biopharma Partnership by Upfront Cash and Equity May 2021 Agenus development and commercialization deal with BMS for AGEN-1777...
by DealForma Analysts | Apr 30, 2021 | Deal of the Month
Deal of the Month Top Biopharma Deal April 2021: CRISPR – Vertex for CTX001 for Sickle Cell Disease and Transfusion-Dependent Beta-Thalassemia Top Biopharma Partnership by Upfront Cash and Equity April 2021 CRISPR Therapeutics amending its development and...
